Skip to main content
Wanbury Limited logo

Wanbury Limited — Investor Relations & Filings

Ticker · WANBURY ISIN · INE107F01022 LEI · 335800QB384KGMBID276 BSE.NS Manufacturing
Open in API
Filings indexed 918 across all filing types
Latest filing 2026-06-09 Regulatory Filings
Country IN India
Listing BSE.NS WANBURY

About Wanbury Limited

https://www.wanbury.com

Wanbury Limited specializes in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and finished formulations. The organization maintains a significant global presence, particularly as a leading producer of Metformin. Its product portfolio spans diverse therapeutic areas, including gynecology, orthopedics, hematinics, and anti-diabetics. The company operates manufacturing facilities compliant with international regulatory standards, including the USFDA. Wanbury focuses on providing medicinal solutions through integrated research and development capabilities and large-scale production infrastructure, serving both domestic and international markets with a range of specialty products.

Recent filings

Filing Released Lang Actions
Press Release
Regulatory Filings Classification · 73% confidence The document is a letter addressed to BSE and NSE under Regulation 30 of SEBI LODR, providing a press release on the launch of new Active Pharmaceutical Ingredients (APIs). It is a routine regulatory announcement to the stock exchanges, not a full report or other specific category. This fits the fallback “Regulatory Filings (RNS)” category for miscellaneous compliance announcements.
2026-06-09 English
Press Release on Launch of New APIs.
Regulatory Filings Classification · 88% confidence The document is a stock exchange disclosure under SEBI LODR Regulation 30, announcing a press release on the launch of new APIs and regulatory filings (DMFs) and an audit inspection result. It does not contain financial statements, management changes, dividends, or details of a specific report attached or published. Therefore it is a general regulatory announcement, fitting the Regulatory Filings (RNS) category.
2026-06-09 English
Pursuant to Regulation 30 (6) of SEBI (Listing Obligation and Disclosure Requirements) Regulation, we wish to inform you that the Company is organizing a plant visit and management meeting ....
Regulatory Filings Classification · 75% confidence The document is a letter to the stock exchanges under SEBI LODR Regulation 30(6) disclosing the schedule of upcoming analyst/investor meetings (site visit and group meeting). It provides logistical details (date, type of meeting, participants) but contains no financial results or substantive report content. It is an exchange regulatory announcement rather than a full report or presentation. Therefore it falls under the generic Regulatory Filings category.
2026-06-02 English
Investor Presentation
Regulatory Filings Classification · 75% confidence The document is a SEBI LODR Regulation 30(6) disclosure to stock exchanges providing the schedule of an analyst/investor meeting (plant visit). It does not contain financial results or detailed presentations, nor is it a formal report, but a regulatory compliance announcement. It does not match other specific categories (10-K, IR, ER, IP, etc.), so it falls under the fallback category for general regulatory announcements: RNS.
2026-06-02 English
Press Release on Q4 & Year ended FY 2026 for Audited Financial Results
Earnings Release Classification · 91% confidence The document is a press release announcing the audited financial results for Q4 and full year ended March 31, 2026, with summary financial highlights (revenue, EBITDA, PAT, EPS), quarter and year comparisons, and management commentary. It does not contain the full annual report or detailed financial statements, but provides key metrics and narrative – fitting the definition of an Earnings Release (initial announcement of periodic financial results). FY 2026
2026-06-02 English
Press Release
Earnings Release Classification · 90% confidence The document is a press release issued under SEBI LODR Regulation 30 announcing the audited financial results for Q4 and full year FY26 with key metrics (revenue, EBITDA, PAT, EPS) and management commentary. It contains summary tables and highlights rather than full statutory financial statements, fitting the definition of an initial Earnings Release. FY 2026
2026-06-02 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.